A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Status:
Not yet recruiting
Trial end date:
2023-12-04
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches
the bloodstream and the time it takes for the body to get rid of it when given to
participants with renal (kidney) impairment compared to participants with normal renal
function. The safety and tolerability of LY3473329 will also be evaluated in these
participants. The study will last up to 8 weeks including screening period.